JP2007522177A - 血管新生を伴う疾病の治療のためのo−ATPの使用 - Google Patents
血管新生を伴う疾病の治療のためのo−ATPの使用 Download PDFInfo
- Publication number
- JP2007522177A JP2007522177A JP2006552566A JP2006552566A JP2007522177A JP 2007522177 A JP2007522177 A JP 2007522177A JP 2006552566 A JP2006552566 A JP 2006552566A JP 2006552566 A JP2006552566 A JP 2006552566A JP 2007522177 A JP2007522177 A JP 2007522177A
- Authority
- JP
- Japan
- Prior art keywords
- atp
- treatment
- angiogenesis
- diseases
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Toilet Supplies (AREA)
- Photoreceptors In Electrophotography (AREA)
- Compositions Of Oxide Ceramics (AREA)
Abstract
【選択図】なし
Description
内皮細胞の増殖は、血管新生として知られる新しい血管の形成のプロセスを担っている。新しく作られた血管は、血管新生が起こる組織の細胞に、栄養分及び酸素を供給する。再生組織は適当な血液供給を必要とするため、血管新生のプロセスは、例えば、傷の修復に有用である。一方、血液供給が腫瘍細胞の増殖を促進するため、血管新生は、腫瘍疾患の場合には有害となる。さらに、アテローム動脈硬化性のプラークに進展する場合、血管新生は有害となる。実際、これらの組織では、内皮及び他の細胞によるVEGF(脈管内皮成長因子)生成のための新しい血管の発生は、単球/大食細胞として、同じプラークの保存を支持する。従って、内皮細胞増殖の抑制または血管新生を阻害する作用は、抗腫瘍及び抗アテローム硬化症の治療に対する注目に値する関心事である。
o−ATPとして知られるATPの酸化形態は、リボフラノシル(ribofuranosyl)環の2’及び3’位での2つのアルデヒド基の存在によって特徴付けられる。P.N. Loweらによって"Preparation and chemical properties of periodate-oxidized adenosine triphosphate and some related compounds", Biochemical Society Transactions, vol. 7: 1131-1133,1979で開示されたように、それは、ATPを過ヨウ素酸塩で処理することにより形成することができる。
WO02/11737号において、同出願人は、実験的なモデルとして、完全なフロイントアジュバント(CFA)の足底注射に起因するネズミ足の片側の炎症を使用して、o−ATP抗炎症性及び鎮痛性の影響を開示している。
ヒト内皮細胞(HUVEC)を、臍静脈から分離し、計数し、96ウェルプレート中に、一定の数で接種した。VEGF(50ng/ml)の有無(対照)、つまり、o−ATP(100μM)及びo−ATP+VEGFの存在下、開示されているようにして(Jaffe, E. A. (1984) Biology of Endothelial Cells, Martinus Nighoff Publisher, Boston, USA, pp. 1-260)、細胞を培養した。刺激の有無による24時間の培養の後、細胞を洗浄し、バーカーチャンバを用いて光学顕微鏡で計数した。その結果を図1に示す。10の実験の平均+SDを表している。
細胞培養用のトランスウェル・チャンバ(ポリカーボネートフィルター0.4μm、Costar)を用いた。要するに、融合性内皮細胞は、単分子層で、1時間、VEGF、o−ATP、ATP(300μM)、ATP+o−ATP、o−ATP+VEGFにさらされ(予め、上述した濃度で)、完全に洗浄した。125I(NEN、ボストン、MA)で標識されたアルブミンを、上部コンパートメントに加え、冷却したアルブミン(1.5mg/ml)を、トランスサイトーシスを最小にするために、培養液に加えた。l25I−標識アルブミンの各ウェルへの添加の1時間後に、サンプルをコンパートメント下方から採取した。サンプルの放射能は、ガンマカウンター(パッカード、スターリング、VA)で測定した。その結果は、図2に示しており、10の独立した実験の平均+SDを表わし、移動した内皮細胞のパーセンテージとして表した。
Claims (6)
- 抗血管新生活性を有する医薬の製造のためのo−ATPの使用。
- 血管新生が発症又は悪化する疾病の治療用である請求項1の使用。
- 眼性疾患、アテローム性動脈硬化症プロセス又は腫瘍の治療用である請求項1又は2の使用。
- 癌腫、リンパ腫、白血病、肉腫、黒色腫、神経膠腫、神経芽細胞腫の治療用である請求項3の使用。
- 腫瘍治療において同時、別個又は連続使用するための、細胞毒性又は細胞増殖抑制化合物、代謝拮抗物質、アルカロイド、抗生物質、アルキル化剤、ペプチド、生物学的応答モジュレータ及びサイトカインから選択される抗腫瘍物質との組み合わせでo−ATPを含有する治療剤。
- 腫瘍治療において同時、別個又は連続使用するための、薬剤とスタチンを低下させる脂質から選択される抗アテローム性動脈硬化性物質との組み合わせでo−ATPを含有する治療剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000255A ITMI20040255A1 (it) | 2004-02-17 | 2004-02-17 | Sostanze ad attivita' antiangiogenica |
PCT/EP2005/001458 WO2005077383A1 (en) | 2004-02-17 | 2005-02-14 | The use of o-atp for the treatment of diseases involving angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007522177A true JP2007522177A (ja) | 2007-08-09 |
Family
ID=34856914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006552566A Pending JP2007522177A (ja) | 2004-02-17 | 2005-02-14 | 血管新生を伴う疾病の治療のためのo−ATPの使用 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070099864A1 (ja) |
EP (1) | EP1732574B1 (ja) |
JP (1) | JP2007522177A (ja) |
KR (1) | KR20070007786A (ja) |
CN (1) | CN1917887A (ja) |
AT (1) | ATE456371T1 (ja) |
AU (1) | AU2005211924A1 (ja) |
BR (1) | BRPI0507738A (ja) |
CA (1) | CA2556601A1 (ja) |
DE (1) | DE602005019142D1 (ja) |
ES (1) | ES2336011T3 (ja) |
IT (1) | ITMI20040255A1 (ja) |
NO (1) | NO20063686L (ja) |
PL (1) | PL1732574T3 (ja) |
RU (1) | RU2359679C2 (ja) |
WO (1) | WO2005077383A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3041260B1 (fr) * | 2015-09-21 | 2020-10-02 | Hopitaux Paris Assist Publique | Utilisation d'un tripeptide cyclique pour stimuler l'activite mitochondriale de cellules |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002011737A2 (en) * | 2000-08-04 | 2002-02-14 | Universita' Degli Studi Di Milano | Anti-inflammatory medicament |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5324731A (en) * | 1989-02-14 | 1994-06-28 | Amira, Inc. | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated |
PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
WO2003042190A1 (en) * | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
US20050053612A1 (en) * | 2003-08-20 | 2005-03-10 | Granstein Richard D. | Nucleotide regulation of immune responses |
-
2004
- 2004-02-17 IT IT000255A patent/ITMI20040255A1/it unknown
-
2005
- 2005-02-14 AU AU2005211924A patent/AU2005211924A1/en not_active Abandoned
- 2005-02-14 CA CA002556601A patent/CA2556601A1/en not_active Abandoned
- 2005-02-14 US US10/589,621 patent/US20070099864A1/en not_active Abandoned
- 2005-02-14 DE DE602005019142T patent/DE602005019142D1/de active Active
- 2005-02-14 PL PL05707370T patent/PL1732574T3/pl unknown
- 2005-02-14 WO PCT/EP2005/001458 patent/WO2005077383A1/en active Application Filing
- 2005-02-14 BR BRPI0507738-9A patent/BRPI0507738A/pt not_active IP Right Cessation
- 2005-02-14 AT AT05707370T patent/ATE456371T1/de not_active IP Right Cessation
- 2005-02-14 CN CNA2005800050438A patent/CN1917887A/zh active Pending
- 2005-02-14 JP JP2006552566A patent/JP2007522177A/ja active Pending
- 2005-02-14 KR KR1020067016477A patent/KR20070007786A/ko not_active Application Discontinuation
- 2005-02-14 RU RU2006129748/15A patent/RU2359679C2/ru not_active IP Right Cessation
- 2005-02-14 ES ES05707370T patent/ES2336011T3/es active Active
- 2005-02-14 EP EP05707370A patent/EP1732574B1/en not_active Not-in-force
-
2006
- 2006-08-16 NO NO20063686A patent/NO20063686L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002011737A2 (en) * | 2000-08-04 | 2002-02-14 | Universita' Degli Studi Di Milano | Anti-inflammatory medicament |
Also Published As
Publication number | Publication date |
---|---|
ITMI20040255A1 (it) | 2004-05-17 |
ATE456371T1 (de) | 2010-02-15 |
PL1732574T3 (pl) | 2010-07-30 |
CA2556601A1 (en) | 2005-08-25 |
EP1732574A1 (en) | 2006-12-20 |
NO20063686L (no) | 2006-08-16 |
CN1917887A (zh) | 2007-02-21 |
DE602005019142D1 (de) | 2010-03-18 |
US20070099864A1 (en) | 2007-05-03 |
EP1732574B1 (en) | 2010-01-27 |
WO2005077383A1 (en) | 2005-08-25 |
RU2006129748A (ru) | 2008-02-27 |
RU2359679C2 (ru) | 2009-06-27 |
AU2005211924A1 (en) | 2005-08-25 |
BRPI0507738A (pt) | 2007-07-10 |
KR20070007786A (ko) | 2007-01-16 |
ES2336011T3 (es) | 2010-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2377066T3 (es) | Composición terapéutica que contiene al menos un derivado de la pirrobenzodiacepina y la fludarabina | |
EP2051703B1 (en) | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit | |
ES2361566T3 (es) | Uso de inhibidores de parp-1. | |
JP2024037891A (ja) | 黒色腫の治療のための組合せ医薬 | |
EP2603222B1 (en) | Combinatory cancer treatment | |
EP2512469B1 (en) | 3-(indolyl)-or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarzinoma | |
EP2177223B9 (en) | Homoharringtonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to protein kinase inhibitors other than STI 571 | |
RU2492862C2 (ru) | Противоопухолевые средства с бензофенантридиновой структурой и содержащие их препараты | |
CA3076023A1 (en) | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer | |
EP3703755A1 (en) | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use | |
JP2008501007A (ja) | 異常な細胞増殖を治療するための方法 | |
JP2007522177A (ja) | 血管新生を伴う疾病の治療のためのo−ATPの使用 | |
US6602881B2 (en) | Anti-inflammatory uses of manzamines | |
JP5698741B2 (ja) | 13a−(S)脱酸チロホリニンの塩、医薬組成物と用途 | |
WO2017063209A1 (zh) | 曲西立滨和/或其代谢产物治疗携带flt3突变型基因的急性白血病的用途 | |
JP2010155861A (ja) | 末梢神経系の疾患の治療のためのピリミジンヌクレオチドの使用 | |
MXPA06009310A (en) | The use of o-atp for the treatment of diseases involving angiogenesis | |
US20100168050A1 (en) | Compounds having antiangiogenic activity | |
KR20020068260A (ko) | β-2',3'-디데하이드로-2',3'-디데옥시-5-플루오로사이티딘에 의해 선택된 HIV-1 돌연변이 | |
TW201307330A (zh) | 治療乳腺癌之藥物組合 | |
KR20080053317A (ko) | 라미부딘, 스타부딘 및 네비라핀을 포함하는 약학적 조합물 | |
JP2024516848A (ja) | 血液がんを処置する方法 | |
TWI331993B (en) | Aminocyclohexyl ether compounds and uses thereof | |
Zingg | Relevance of the PI3K/Akt survival signaling in the cellular stress response to ionizing radiation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080122 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110719 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111019 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111026 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120207 |